Document is current
Any future updates will be listed below
-
Authors
Larocca, Cecilia
Bui, Ai-Tram N.
O’Malley, John T.
Giobbie-Hurder, Anita
Tawa, Marianne
Teague, Jessica E.
Clark, Rachael A.
Cutler, Corey https://orcid.org/0000-0001-8728-4314
Jacobsen, Eric
Fisher, David C. https://orcid.org/0000-0001-6915-8584
Kupper, Thomas S.
LeBoeuf, Nicole R. https://orcid.org/0000-0002-8264-834X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA203721, R01 CA203721)
David Lamb Fund for Cutaneous T-Cell Lymphoma Research
- License Information
-
More Information
Article History
Received: 16 May 2024
Revised: 6 December 2024
Accepted: 18 February 2025
First Online: 17 April 2025
Competing interests
: NRL is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics outside the submitted work. TSK is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR065807 and T32 AR007098) and the National Institute of Allergy and Infectious Diseases (grant number R01 AI127654); he is a scientific advisor for Pellis Therapeutics. CL is supported by the National Cancer Institute (grant number R37 CA252312). She has served on a medical advisory board for Kyowa Kirin. JOM is an employee of Sanofi and may hold stock and/or stock options in the company. RC, DF, and EJ have no conflicts of interest to disclose.
: All methods were performed in accordance with the relevant guidelines and regulations. Approval was obtained from institutional review board (DFCI protocol #02-016) and informed patient consent was obtained from all participants for study, including for translational research investigations.
